ketoconazole
E850010
Ketoconazole is an imidazole antifungal medication that inhibits ergosterol synthesis and strongly blocks CYP3A4-mediated drug metabolism.
Statements (73)
| Predicate | Object |
|---|---|
| instanceOf |
antifungal drug
ⓘ
azole antifungal ⓘ imidazole derivative ⓘ |
| affects | cytochrome P450–mediated drug metabolism ⓘ |
| canDecreaseSynthesisOf |
cortisol
ⓘ
testosterone ⓘ |
| hasAdministrationNote | oral systemic use has been largely restricted due to hepatotoxicity risk ⓘ |
| hasAdverseEffect |
abdominal pain
ⓘ
elevated liver enzymes ⓘ gynecomastia ⓘ hepatotoxicity ⓘ nausea ⓘ pruritus ⓘ rash ⓘ vomiting ⓘ |
| hasATCCode |
D01AC08
ⓘ
G01AF11 ⓘ J02AB02 ⓘ |
| hasBioavailability | variable oral bioavailability ⓘ |
| hasBlackBoxWarningFor |
hepatotoxicity
ⓘ
risk of severe liver injury ⓘ |
| hasBrandName | Nizoral NERFINISHED ⓘ |
| hasCASNumber | 65277-42-1 ⓘ |
| hasChemicalClass |
azole
ⓘ
imidazole ⓘ |
| hasDosageForm |
cream
ⓘ
foam ⓘ gel ⓘ shampoo ⓘ tablet ⓘ |
| hasDrugInteractionMechanism | CYP3A4 inhibition ⓘ |
| hasDrugInteractionWith |
cisapride
NERFINISHED
ⓘ
dofetilide NERFINISHED ⓘ lovastatin ⓘ midazolam NERFINISHED ⓘ pimozide NERFINISHED ⓘ quinidine NERFINISHED ⓘ simvastatin NERFINISHED ⓘ triazolam NERFINISHED ⓘ |
| hasEliminationHalfLife | approximately 2 to 8 hours ⓘ |
| hasMechanismOfAction | inhibition of ergosterol synthesis ⓘ |
| hasMolarMass | 531.43 g/mol ⓘ |
| hasMolecularFormula | C26H28Cl2N4O4 ⓘ |
| hasOffLabelUse |
Cushing syndrome
NERFINISHED
ⓘ
prostate cancer (hormonal therapy adjunct) ⓘ |
| hasPregnancyCategory | C (US, historical) ⓘ |
| hasRouteOfAdministration |
oral
ⓘ
topical ⓘ |
| inhibits |
CYP17A1
NERFINISHED
ⓘ
CYP3A4 NERFINISHED ⓘ ergosterol biosynthesis in fungi ⓘ lanosterol 14α-demethylase NERFINISHED ⓘ |
| isAcidDependentForAbsorption | true ⓘ |
| isContraindicatedIn |
acute liver disease
ⓘ
chronic liver disease ⓘ |
| isExcretedVia |
bile
ⓘ
feces ⓘ urine ⓘ |
| isHighlyProteinBound | true ⓘ |
| isMetabolizedBy |
CYP3A4
NERFINISHED
ⓘ
liver ⓘ |
| isStrongInhibitorOf | CYP3A4 ⓘ |
| targets | lanosterol 14α-demethylase NERFINISHED ⓘ |
| treats |
cutaneous candidiasis
ⓘ
dandruff ⓘ dermatophytosis ⓘ pityriasis versicolor NERFINISHED ⓘ seborrheic dermatitis ⓘ tinea corporis ⓘ tinea cruris ⓘ tinea pedis ⓘ tinea versicolor ⓘ |
| wasFirstApprovedIn | 1981 (US) ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.